Dependence on the Contract with Charles River for Outsourced U.S. Pharmaceutical Production
First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2020.
0 other companies' latest entry also says "Dropped".
- FY2020DroppedAnnual report
「Began outsourcing the production of PXB mice to Charles River Laboratories,Inc. in the United States in March 2015」
The U.S. production outsourcing arrangement with Charles River remains in the strategic description, but the risk of termination of the agreement, which had previously been disclosed, is no longer listed as a separate risk item. - FY2018RestatedAnnual report
「The Company has entered into a production outsourcing agreement with Charles River Laboratories,Inc. for the production of PXB mice in the United States. …If this agreement is terminated, the Company may be forced to change its business plan, which could affect the business development and performance of the Group.」
The risk of depending on the outsourcing agreement with Charles River for U.S. production is being reassessed. - FY2017RestatedAnnual report
「If this agreement is terminated, the Company may be forced to change its business plan, which could affect the business development and performance of the Group.」
The risk of dependence on the U.S. production outsourcing agreement with Charles River is being reassessed. - FY2016First statedAnnual report
「The Company has entered into a production outsourcing agreement with Charles River Laboratories,Inc. for the production of PXB mice in the United States. …If this agreement is terminated, the Company may be forced to change its business plan, which could affect the business development and performance of the Group.」
The Company depends on a key agreement for U.S. production and identifies changes to its business plan if the agreement is terminated as a risk.